U.S. Markets open in 1 hr 52 mins

Magenta Therapeutics, Inc. (MGTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.82+1.11 (+9.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.71
Open11.06
Bid12.80 x 900
Ask12.81 x 1100
Day's Range11.38 - 13.10
52 Week Range6.03 - 13.69
Volume474,241
Avg. Volume321,591
Market Cap623.093M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateMar 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
  • Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
    Business Wire

    Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors

    Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional investors in a private placement. Magenta anticipates aggregate gross proceeds from the offering will be $86.4 million, before deducting estimated offering expenses payable by the Company, based on the offering price of $9.00 per share. The financing syndicate includes Deep Track Capital, L.P., TCG X, Great Point Partners, LLC, OrbiMed and Janus Henderson Investors. The closing is anticipated to occur on May 14, 2021, subject to customary closing conditions. Magenta intends to use the net proceeds from the offering for general corporate purposes and working capital.

  • Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
    Business Wire

    Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117

    Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma, which were accepted for presentation at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021. Magenta also provided initial direction regarding the acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients it expects to evaluate in its planned clinical trial with MGTA-117.

  • Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
    Business Wire

    Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights

    Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the first quarter ended March 31, 2021 and recent program highlights.